Barrington Research Boosts LeMaitre Vascular (NASDAQ:LMAT) Price Target to $92.00

LeMaitre Vascular (NASDAQ:LMAT) had its target price boosted by investment analysts at Barrington Research from $79.00 to $92.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price target would indicate a potential upside of 8.22% from the stock’s current price.

A number of other equities research analysts also recently weighed in on LMAT. Roth Mkm reaffirmed a “buy” rating and issued a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday. They issued a “buy” rating and a $105.00 target price on the stock. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Finally, JMP Securities raised their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $83.71.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded down $1.24 during mid-day trading on Friday, reaching $85.01. The company had a trading volume of 348,354 shares, compared to its average volume of 128,845. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 56.30, a PEG ratio of 2.65 and a beta of 0.89. The business’s 50-day simple moving average is $82.59 and its 200 day simple moving average is $71.48. LeMaitre Vascular has a one year low of $44.27 and a one year high of $91.76.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The firm had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same period last year, the firm earned $0.37 EPS. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, sell-side analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the transaction, the chief executive officer now owns 2,079,128 shares in the company, valued at approximately $156,558,338.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 8,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total transaction of $602,400.00. Following the sale, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at $156,558,338.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.62, for a total value of $379,990.50. Following the completion of the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at $1,067,300.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 127,437 shares of company stock valued at $10,076,242. 10.79% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

Several large investors have recently modified their holdings of the stock. Shaker Investments LLC OH boosted its stake in LeMaitre Vascular by 1.3% during the first quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 169 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares in the last quarter. nVerses Capital LLC grew its stake in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares during the period. Albion Financial Group UT increased its position in LeMaitre Vascular by 5.6% in the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after buying an additional 212 shares in the last quarter. Finally, Texas Permanent School Fund Corp raised its stake in LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after buying an additional 225 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.